Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Hemophilia Market, by Distribution Channel
1.4.2 Europe Hemophilia Market, by Type
1.4.3 Europe Hemophilia Market, by Treatment Type
1.4.4 Europe Hemophilia Market, by Therapy
1.4.5 Europe Hemophilia Market, by Country
1.5 Methodology for the research
Chapter 2. Market At a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Europe Hemophilia Market by Distribution Channel
5.1 Europe Specialty Pharmacies Market by Country
5.2 Europe Hospital Pharmacies Market by Country
Chapter 6. Europe Hemophilia Market by Type
6.1 Europe Hemophilia A Market by Country
6.2 Europe Hemophilia B Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Hemophilia Market by Treatment Type
7.1 Europe Prophylaxis Market by Country
7.2 Europe On-demand Market by Country
7.3 Europe Cure Market by Country
Chapter 8. Europe Hemophilia Market by Therapy
8.1 Europe Factor Replacement Therapy Market by Country
8.2 Europe Hemophilia Market by Factor Replacement Therapy Type
8.2.1 Europe Recombinant Factor Concentrates Market by Country
8.2.2 Europe Plasma-derived Factor Concentrates Market by Country
8.3 Europe Desmopressin & Fibrin Sealants Market by Country
8.4 Europe Gene Therapy & Monoclonal Antibodies Market by Country
Chapter 9. Europe Hemophilia Market by Country
9.1 Germany Hemophilia Market
9.1.1 Germany Hemophilia Market by Distribution Channel
9.1.2 Germany Hemophilia Market by Type
9.1.3 Germany Hemophilia Market by Treatment Type
9.1.4 Germany Hemophilia Market by Therapy
9.1.4.1 Germany Hemophilia Market by Factor Replacement Therapy Type
9.2 UK Hemophilia Market
9.2.1 UK Hemophilia Market by Distribution Channel
9.2.2 UK Hemophilia Market by Type
9.2.3 UK Hemophilia Market by Treatment Type
9.2.4 UK Hemophilia Market by Therapy
9.2.4.1 UK Hemophilia Market by Factor Replacement Therapy Type
9.3 France Hemophilia Market
9.3.1 France Hemophilia Market by Distribution Channel
9.3.2 France Hemophilia Market by Type
9.3.3 France Hemophilia Market by Treatment Type
9.3.4 France Hemophilia Market by Therapy
9.3.4.1 France Hemophilia Market by Factor Replacement Therapy Type
9.4 Russia Hemophilia Market
9.4.1 Russia Hemophilia Market by Distribution Channel
9.4.2 Russia Hemophilia Market by Type
9.4.3 Russia Hemophilia Market by Treatment Type
9.4.4 Russia Hemophilia Market by Therapy
9.4.4.1 Russia Hemophilia Market by Factor Replacement Therapy Type
9.5 Spain Hemophilia Market
9.5.1 Spain Hemophilia Market by Distribution Channel
9.5.2 Spain Hemophilia Market by Type
9.5.3 Spain Hemophilia Market by Treatment Type
9.5.4 Spain Hemophilia Market by Therapy
9.5.4.1 Spain Hemophilia Market by Factor Replacement Therapy Type
9.6 Italy Hemophilia Market
9.6.1 Italy Hemophilia Market by Distribution Channel
9.6.2 Italy Hemophilia Market by Type
9.6.3 Italy Hemophilia Market by Treatment Type
9.6.4 Italy Hemophilia Market by Therapy
9.6.4.1 Italy Hemophilia Market by Factor Replacement Therapy Type
9.7 Rest of Europe Hemophilia Market
9.7.1 Rest of Europe Hemophilia Market by Distribution Channel
9.7.2 Rest of Europe Hemophilia Market by Type
9.7.3 Rest of Europe Hemophilia Market by Treatment Type
9.7.4 Rest of Europe Hemophilia Market by Therapy
9.7.4.1 Rest of Europe Hemophilia Market by Factor Replacement Therapy Type
Chapter 10. Company Profiles
10.1 Swedish Orphan Biovitrum AB (Investor AB)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 SWOT Analysis
10.2 Takeda Pharmaceutical Company Limited
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Trials and Approvals:
10.2.5.2 Product Launches and Product Expansions:
10.3 Pfizer, Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional & Segmental Analysis
10.3.4 Research & Development Expense
10.3.4.1 Partnerships, Collaborations, and Agreements:
10.3.4.2 Acquisition and Mergers:
10.4 CSL Limited (CSL Behring)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Trials and Approvals:
10.4.5.2 Acquisition and Mergers:
10.4.6 SWOT Analysis
10.5 Octapharma AG
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Research & Development Expenses
10.5.4 Recent strategies and developments:
10.5.4.1 Trials and Approvals:
10.5.5 SWOT Analysis
10.6 Bayer AG
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.6.5.2 Acquisition and Mergers:
10.6.6 SWOT Analysis
10.7 F. Hoffmann-La Roche Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.7.5 SWOT Analysis
10.8 Novo Nordisk A/S
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental & Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Product Launches and Product Expansions:
10.8.5.3 Acquisition and Mergers:
10.8.6 SWOT Analysis
10.9 BioMarin Pharmaceutical Inc.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.9.4 Research & Development Expenses
10.9.5 Recent strategies and developments:
10.9.5.1 Trials and Approvals:
10.9.6 SWOT Analysis
10.10. Sanofi S.A.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent strategies and developments:
10.10.5.1 Trials and Approvals:
Unique Offerings 